• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears AI-powered ultrasound guidance tech from UltraSight

FDA clears AI-powered ultrasound guidance tech from UltraSight

July 27, 2023 By Sean Whooley

UltraSight AI-powered ultrasound guidance system
AI-powered ultrasound guidance software. [Image from the UltraSight website]
UltraSight announced today that it received FDA clearance for its AI-powered ultrasound guidance technology.

Tel Aviv, Israel-based UltraSight designed its real-time AI guidance software to assist in the acquisition of cardiac ultrasound images. It can help medical professionals without sonography experience at the point of care in multiple settings. UltraSight says it allows for more widespread heart disease detection, providing patients with easier access to cardiac monitoring.

“The issues arising from the disproportion between the number of heart disease patients and availability of cardiac ultrasound was a key driver for the company’s founding team,” said Davidi Vortman, CEO of UltraSight. “The need to solve this significant disparity is why we applied deep geometrical machine-learning techniques to cardiac ultrasound, and what we found is that AI has the potential to close the skillset gap – empowering medical professionals to successfully acquire timely and accurate cardiac ultrasound images anywhere.

“With FDA clearance, we can now move forward with bringing our innovation to market and ultimately advancing patient care for the millions in need.”

More about the UltraSight AI-powered technology

The company said its solution enables hospital staff to advance patient triage and treatment with more efficiency and clinical confidence. It could also increase access to care for chronic heart disease patients by bringing cardiac ultrasound to local communities. This may increase patient adherence to critical treatments, UltraSight said.

FDA clearance covers use in two-dimensional transthoracic echocardiography (2D-TTE) for adult patients. It specifically grants authorization for the system’s use in the acquisition of the 10 standard views of the heart. Clinical data demonstrated that, with real-time guidance of the ultrasound probe and feedback on image quality, medical professionals without prior ultrasound experience can acquire diagnostic-quality images.

UltraSight designed its software as an accessory for point-of-care ultrasound systems. It has compatibility with the Philips Lumify ultrasound system. When paired with a compatible device, UltraSight’s underlying AI network predicts the position of the ultrasound probe. It predicts this position relative to the heart based on the ultrasound video stream. The software then guides the user on maneuvering the probe to capture diagnostic-quality cardiac images.

Filed Under: Food & Drug Administration (FDA), Health Technology, Imaging, Regulatory/Compliance, Software / IT, Ultrasound Tagged With: UltraSight

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy